Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 4712  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (426 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References

 Article Access Statistics
    Viewed1266    
    Printed22    
    Emailed0    
    PDF Downloaded41    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
CORRESPONDENCE
Year : 2017  |  Volume : 65  |  Issue : 4  |  Page : 921

Management of brain tumour-related epilepsy: Rationale for labelling the first line medications


Department of Neurosurgery, G.B. Pant Institute of Post Graduate Medical Education and Research (G.I.P.M.E.R.), New Delhi, India

Date of Web Publication5-Jul-2017

Correspondence Address:
Daljit Singh
Department of Neurosurgery, G.B. Pant Institute of Post Graduate Medical Education and Research (G.I.P.M.E.R.), Room No. 529, Department of Neurosurgery, G.B. Pant Institute of Post Graduate Medical Education and Research (G.I.P.M.E.R.), Jawaharlal Nehru Marg, New Delhi - 110 002, Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/neuroindia.NI_423_17

Rights and Permissions



How to cite this article:
Ansari M T, Shah AS, Garg M, Singh D. Management of brain tumour-related epilepsy: Rationale for labelling the first line medications. Neurol India 2017;65:921

How to cite this URL:
Ansari M T, Shah AS, Garg M, Singh D. Management of brain tumour-related epilepsy: Rationale for labelling the first line medications. Neurol India [serial online] 2017 [cited 2019 Dec 16];65:921. Available from: http://www.neurologyindia.com/text.asp?2017/65/4/921/209507




Sir,

We have read the article entitled “Management of brain tumour-related epilepsy,” published in Neurology India, 2017, Vol. 65; Supplement 1 by Drs. Neil V. Klinger, Aashit Shah and Sandeeep Mittal.[1] First of all, we want to congratulate the authors for this article. We have few queries regarding the classification of antiepileptic drugs [Table 2] made in this article.{Table 2}

As per the classification presented in the article, drugs namely, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, pregabalin and topiramate have been placed as first line medications, and drugs namely, carbamazepine, phenobarbital, phenytoin and valproic acid has been placed as second line medications.

Drugs like phenytoin, carbamazepine and valporic acid, which have been classified by author as second line medications for epilepsy, are used very commonly, as these are better tolerated, easily available, highly cost effective and have fewer side-effects on a maintenance dose.[2],[3]

Levetiracetam and lacosamide are new antiepileptic drugs and we have less experience in their usage and no large randomized clinical study have been done so far to label them as first line medications. What is the basis upon which these medications been categorized by the authors as first line antiepileptic drugs?

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Klinger NV, Shah AK, Mittal S. Management of brain tumor-related epilepsy. Neurol India 2017;65(Suppl) S1:60-70.  Back to cited text no. 1
    
2.
Rathore C, Radhakrishnan K. Epidemiology of epilepsy surgery in India. Neurol India 2017;65(Suppl) S1:52-9.  Back to cited text no. 2
    
3.
Radhakrishnan A. Bridging the treatment gap in epilepsy-is there an emerging trend in the use of newer antiepileptic drugs? Neurol India 2016;64:1140-2.  Back to cited text no. 3
[PUBMED]  [Full text]  




 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow